<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Ardea Biosciences</title>
	<atom:link href="http://www.stockbloghub.com/tag/ardea-biosciences/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Mon, 21 May 2012 16:42:30 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(RDEA) Ardea Biosciences Analyst Maintains Neutral Rating</title>
		<link>http://www.stockbloghub.com/2010/08/18/rdea-ardea-biosciences-analyst-maintains-neutral-rating/48247</link>
		<comments>http://www.stockbloghub.com/2010/08/18/rdea-ardea-biosciences-analyst-maintains-neutral-rating/48247#comments</comments>
		<pubDate>Wed, 18 Aug 2010 18:38:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Ardea Biosciences]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[RDEA]]></category>
		<category><![CDATA[Regeneron Pharmaceuticals Inc]]></category>
		<category><![CDATA[REGN]]></category>
		<category><![CDATA[Savient Pharmaceuticals Inc]]></category>
		<category><![CDATA[SVNT]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=48247</guid>
		<description><![CDATA[We are maintaining our Neutral recommendation on Ardea Biosciences Inc. (RDEA) with a target price of $20. Ardea Biosciences, headquartered in San Diego, CA, focuses on the discovery and development of small-molecule therapeutics for the treatment of gout, human immunodeficiency virus (HIV) and cancer. Ardea recently reported disappointing second quarter 2010 results. The development stage biopharmaceutical company’s second-quarter 2010 net loss of $12.8 million, or $0.57 per share was wider than the year-ago loss of $8 million, or $0.44 per share and the Zacks Consensus Estimate of a loss at $0.46. The wider loss at Ardea in the reported quarter was due to the increased amount spent on developing its pipeline coupled with lower revenues in the quarter. Revenue in the reported quarter slipped 36% to $3.5 million. We are pleased with Ardea’s ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/18/rdea-ardea-biosciences-analyst-maintains-neutral-rating/48247/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SVNT) Savient Pharmaceuticals Announces the FDA accepted Biologics License Application</title>
		<link>http://www.stockbloghub.com/2010/04/01/svnt-savient-pharmaceuticals-announces-the-fda-accepted-biologics-license-application/32529</link>
		<comments>http://www.stockbloghub.com/2010/04/01/svnt-savient-pharmaceuticals-announces-the-fda-accepted-biologics-license-application/32529#comments</comments>
		<pubDate>Thu, 01 Apr 2010 15:02:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Ardea Biosciences]]></category>
		<category><![CDATA[RDEA]]></category>
		<category><![CDATA[Savient Pharmaceuticals Inc]]></category>
		<category><![CDATA[SVNT]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32529</guid>
		<description><![CDATA[Recently, Savient Pharmaceuticals, Inc. (SVNT) announced that the U.S. Food and Drug Administration (FDA) accepted the Biologics License Application (BLA) for its gout candidate, Krystexxa (pegloticase). The BLA was resubmitted by Savient on March 15, 2010. A response from the FDA should be out in the fourth quarter of 2010 (target date: Sept 14, 2010). As a reminder, the FDA issued a complete response letter [CRL] in July 2009 whereby the agency refused to approve the BLA for Krystexxa because Savient changed the way the drug was manufactured, among other issues. The resubmission is classified by the FDA as a Class 2 review. The resubmitted application is inclusive of additional chemistry, manufacturing and controls, Safety Update, Labeling, Risk Evaluation and Mitigation Strategy, and Medication Guide, as requested in the complete ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/01/svnt-savient-pharmaceuticals-announces-the-fda-accepted-biologics-license-application/32529/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RDEA) Ardea Biosciences Sees Good News</title>
		<link>http://www.stockbloghub.com/2009/12/02/rdea-ardea-biosciences-sees-good-news/21731</link>
		<comments>http://www.stockbloghub.com/2009/12/02/rdea-ardea-biosciences-sees-good-news/21731#comments</comments>
		<pubDate>Wed, 02 Dec 2009 22:07:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Ardea Biosciences]]></category>
		<category><![CDATA[RDEA]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=21731</guid>
		<description><![CDATA[Recently, Ardea Biosciences, Inc. (RDEA) announced positive results from the first dosing group of a one-week randomized, placebo-controlled drug-combination study in normal healthy volunteers of its candidate for gout treatment, RDEA594 and Uloric (febuxostat) of Takeda. The treatment from the combination gave 20% better results in hyperuricemia (elevated uric acid levels) and gout patients, opposed to single agent therapy. The study (baseline serum urate levels of greater than 5 mg/dL) is designed to evaluate the potential for pharmacokinetic drug interactions, coupled with the serum urate-lowering effect, safety and tolerability of escalating doses of RDEA594 once-daily combined with 40 mg febuxostat. After seven days of dosing as monotherapy, both RDEA594 and febuxostat caused a 40% mean reduction in serum urate from the baseline. However, when they were administered in combination for ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/02/rdea-ardea-biosciences-sees-good-news/21731/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RDEA) Ardea Biosciences Inc. Lowers Loss</title>
		<link>http://www.stockbloghub.com/2009/11/14/rdea-ardea-biosciences-inc-lowers-loss/20450</link>
		<comments>http://www.stockbloghub.com/2009/11/14/rdea-ardea-biosciences-inc-lowers-loss/20450#comments</comments>
		<pubDate>Sun, 15 Nov 2009 00:20:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Ardea Biosciences]]></category>
		<category><![CDATA[RDEA]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20450</guid>
		<description><![CDATA[Ardea Biosciences Inc. (RDEA) reported third quarter net loss of $2.47 million, or 13 cents per share, which was significantly lower than the Zacks Consensus Estimate of 47 cents. The company reported a net loss of $14.2 million or 95 cents in the year-ago period. The lower loss was attributable to the higher revenues coupled with lower operating expenses recorded in the quarter. Revenues came in at $9.17 million as against none in the year-ago quarter. The revenues resulted from the recognition of a portion of the upfront payment of $35 million under the global agreement, with Bayer HealthCare focused on the development of MEK inhibitors for the treatment of cancer. Operating expenses for the quarter decreased 21.4% to $11.4 million primarily due to reduced research and clinical development expenditures. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/14/rdea-ardea-biosciences-inc-lowers-loss/20450/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

